Compound comparisons
Receptor targets and molecular classes from published preclinical literature. Reference only — not health guidance.
Retatrutide vs Tirzepatide vs Semaglutide
These differ by how many receptors they target: semaglutide targets one (GLP-1), tirzepatide two (GIP + GLP-1) and retatrutide three (GIP + GLP-1 + glucagon).
| Compound | Class | Target |
|---|---|---|
| Semaglutide | Acylated GLP-1 analog | GLP-1 receptor |
| Tirzepatide | Synthetic dual-agonist peptide | GIP and GLP-1 receptors |
| Retatrutide | Synthetic peptide tri-agonist | GIP, GLP-1 and glucagon receptors |
BPC-157 vs TB-500
BPC-157 is studied around nitric-oxide and VEGF signaling; TB-500 is a thymosin β4 fragment studied for actin binding and cell migration.
CJC-1295 vs Ipamorelin
CJC-1295 is a GHRH analog acting on the GHRH receptor; ipamorelin is a secretagogue acting on the ghrelin receptor (GHS-R1a).
| Compound | Class | Target |
|---|---|---|
| CJC-1295 | Modified GHRH analog | GHRH receptor |
| Ipamorelin | Selective pentapeptide secretagogue | Ghrelin receptor (GHS-R1a) |
Selank vs Semax
Both are synthetic neuropeptides: selank is a tuftsin analog studied in GABAergic models; semax is an ACTH(4-10) analog studied for BDNF expression.